anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomized, open-label (identity of assigned treatment will be known to participants and study staff), 2-arm (2 treatment groups), multicenter study of daratumumab in participants diagnosed with previously untreated Multiple Myeloma who are eligible for high dose chemotherapy and autologous stem cell transplantation (transplantation of own bone marrow). Participants will be randomized (assigned by chance) to one of 2 treatment groups to either receive daratumumab plus bortezomib, thalidomide and dexamethasone or bortezomib, thalidomide and dexamethasone for induction (before transplantation) and consolidation (after transplantation) treatment. All responders will then be re-randomized (assigned by chance) to one of 2 treatment groups to receive maintenance treatment with daratumumab only or observation (no treatment). The study will include a 28-Day Screening Phase, a Treatment Phase of 6 treatment cycles (each cycle is 4 weeks in duration for total period of 30 weeks), and a Follow up Phase of 2 years. The total duration for each participant in the study will be approximately 138 weeks. The end of the study will occur approximately 5 years after the last participant is randomized in the second phase of the study. Disease assessments will be performed every 4 weeks in the first phase of the study and then every 8 weeks in the second phase of the study. Safety will be monitored throughout the study.
The subjects were 50 elite men's ice hockey players playing in the super league from Turkish clubs subject to Turkey Ice Hockey Federation. All ice hockey players had practicing training programs after warming up for 10 minutes for at least 3 days a week and 1 hour in a day during the season. They also played a match at least 1 day a week. The inclusion criteria were; being a member of Turkish Ice Hockey Federation and to be subject to any of the licensed athletes who played in the super league team, to be over 18, to be male. Exclusion criteria were; being under the age of 18, being a woman, having not suffered a musculoskeletal injury that would prevent him from going to training in the last 1 year or affect the outcome of the measurements.
Life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in NEXVIAZYME-treated patients. In NEXVIAZYME clinical studies, 67 (48%) NEXVIAZYME-treated patients experienced hypersensitivity reactions, including 6 (4%) patients who reported severe hypersensitivity reactions and 3 (2%) patients who experienced anaphylaxis; 2 (1%) patients who experienced anaphylaxis discontinued from the study. Some of the hypersensitivity reactions were IgE mediated. Symptoms of severe hypersensitivity reactions (e.g., anaphylaxis) included chest discomfort, erythema, generalized edema, hypotension, hypoxia, rash, respiratory distress, tongue edema, and urticaria.

Prior to NEXVIAZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during NEXVIAZYME administration.

  * If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue NEXVIAZYME immediately and initiate appropriate medical treatment. Consider the risks and benefits of re-administering NEXVIAZYME following severe hypersensitivity reactions (including anaphylaxis). Patients may be rechallenged using slower infusion rates at a dosage lower than the recommended dosage. In patients with severe hypersensitivity reaction, desensitization measures to NEXVIAZYME may be considered. If the decision is made to readminister NEXVIAZYME, ensure the patient tolerates the infusion. Once the patient tolerates the infusion, the dosage (dose and/or the rate) may be increased to reach the recommended dosage.
  * If a mild or moderate hypersensitivity reaction occurs, consider temporarily holding the infusion or slowing the infusion rate [see Dosage and Administration (2.3)].
A computer program and method for facilitating medical treatment and related billing is disclosed. The computer program is storable, accessible, and executable on a system ( 10 ). The computer program includes a first subprogram ( 16 ) operable to provide a database including medical information for substantially all of the specific groupings of systems of the human body, a second subprogram ( 18 ) operable to provide an input mechanism operable to accept patient data, a third subprogram ( 20 ) operable to correlate the patient data with medical information from one or more of the specific groupings of systems of the human body, and a fourth subprogram ( 22 ) operable to generate a report matching the patient data with the correlated medical information. The computer program provides an input form ( 24 ), that once filled, converts to an output form. An alternative input form ( 42 ) is also disclosed. The inventive program provides a comprehensive and accurate medical history and physical examination of a patient that is efficient and cost effective to complete for the health care provider and formatted in compliance with substantially all third party billing requirements.
Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
A method and system for facilitating healthcare data management between patients, providers, and organizations includes a computerized server having a database, a non-transitory memory, and a processor. A plurality of modules is stored in the database. A scheduling module facilitates the patients and doctors to schedule consultations with one another. A library module stores information accessible to the patients and the providers. A communications module facilitates communication between the patients and the providers. A services module facilitates the patients and the doctors to arrange for services to be completed, wherein the services include at least one of: completion of a lab test, and ordering of medication. A directory module has contact information for the providers and organizations. An engagement module facilitates automated engagement communication between the patients and the providers. A payment module facilitates monetary payments between patients, providers, and organizations.
Subjects will receive Acthar® 40 units twice a week subcutaneously for 2 weeks. If the drug is well tolerated the dose will be increased to 80 units twice a week for another 22 weeks. The patients will be maintained on their center-specific standard maintenance regimen, typically consisting of Tacrolimus, mycephenolate mofetil/Sodium, and prednisone.

After screening for the inclusion/exclusion criteria, the patients will be consented and enrolled in the study. The initial visit and subsequent study-related visits at 4, 8, 12, 24, 36 and 52 weeks will include routine evaluation and physical examination and laboratory studies including CBC (complete blood count), electrolyte panel, eGFR, albumin, liver enzymes, and Calcineurin inhibitor (CNI)/sirolimus drug level, according to the center's standard of care. Donor-specific antibody (DSA) will be tested at week 24, and 52 and patients will undergo a biopsy at week 52, as a part of the investigators standard of care. The biopsies will be evaluated by light and electron microscopy using standard histological Banff criteria, and staining for CD68.
Meta-analyses which evaluated the effects of structured exercise programs in patients with type 2 diabetes demonstrate that regular physical activity improves glycosylated haemoglobin (König et al.: Resistance Exercise and Type 2 Diabetes Mellitus, Deutsche Zeitschrift für Sportmedizin Jahrgang 62, Nr. 1 (2011): 5-9). Sigal et al. proved that either aerobic or resistance training alone improved glycemic control in type 2 diabetes, but the improvements are greatest with combined aerobic and resistance training (Sigal, RJ, et al.: Effects of Aerobic Training, Resistance Training, or Both on Glycemic Control in Type 2 Diabetes, Ann Intern Med. 2007 Sep 18;147(6):357-69).

Therefore, aim of the current study is to compare the effects of aerobic endurance training or resistance endurance training or the combination of aerobic endurance training and resistance endurance training in diabetes type 2 patients without any other lifestyle or dietary interventions.
Drug therapy for secondary lymphedema has not yet been established. Conventional oral and intravenous administration is difficult to administer in sufficient doses due to adverse events. Therefore, it is necessary to develop a transdermal delivery system that can deliver high concentrations of drugs to the edema area. In this study, we examined the efficacy of transdermal drug delivery in a mouse model of tail edema using ultrasound irradiation (sonication method). Ultrasound irradiation can deliver high-molecular-weight substances subcutaneously, and the percutaneous administration of clobetasol propionate to the mouse tail edema model prevented the enlargement of lymphatic vessels with reduced tail volume. Therefore, steroid administration utilizing ultrasound irradiation is effective in decreasing tail swelling in a mouse tail edema model. Thus, ultrasound irradiation could have the potential to innovate the treatment of secondary lymphedema by directly administering the drug to the edema.
PROBLEM TO BE SOLVED: To obtain the subject new physiologically active substances having an insecticidal, a nematicidal and an antitumor activities, and useful for an insecticide, a nematicide, an antitumor agent, etc., by culturing a microorganism belonging to the genus Acremonium having the production capability of the specific new physiologically active substances. SOLUTION: These new physiologically active substances NF02411A and B are colorless powders, having solubilities of easily soluble in dimethylsulfoxide, methanol and chloroform, soluble in acetone, butanol and water and insoluble in n-hexane, ethyl acetate, positive to the color reaction with a sulfuric acid- vanillin reagent, iodine, etc., negative to a ninhydrine reaction, and useful as an insecticide, a nematicide, an antitumor agent, etc., and are obtained by culturing a microorganism belonging to the genus Acremonium having the capability of producing the new physiologically active substances NF02411A and B [e.g. Acremonium sp. NF02411 strain (FERM P-14917), etc.] in a medium to produce and accumulate these products in the medium and collecting the products. Further, the molecular weight of A is 1631 and that of B is 1617.
Physalin H (PH), a withanolide isolated from Physalisangulata L. has been reported to have anti-inflammatory effect. However, its impact on acute lung injury (ALI) remains unexplored. In this study, we observed that PH significantly alleviated inflammation in LPS-stimulated macrophages by suppressing the release of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and down-regulating the expression of the inflammation-related genes. RNA sequencing analysis revealed a significant up-regulation of the NRF2 pathway by PH. Further investigation elucidated that PH attenuated the ubiquitination of NRF2 by impeding the interaction between NRF2 and KEAP1, thereby facilitating NRF2 nuclear translocation and up-regulating the expression of target genes. Consequently, it regulated redox system and exerted anti-inflammatory effect. Consistently, PH also significantly alleviated pathological damage and inflammation in LPS-induced ALI mice model, which could be reversed by administration of an NRF2 inhibitor. Collectively, these results suggest that PH ameliorates ALI by activating the KEAP1/NRF2 pathway. These findings provide a foundation for further development of pH as a new anti-inflammatory agent for ALI therapy.
PURPOSE:To obtain the title composition being excellent in water-resistant self-adhesiveness, flexibility and water absorptivity, nontoxicity and nonirritating and useful as, e.g., a patch for oral mucosa, by dispersing a vinyl acetate (co)polymer, a softener and a water-absorptive polymer particles by kneading under heating. CONSTITUTION:30-200pts.wt. water-absorptive polymer particles (C) of a particle diameter of 1-100mu, at least one member selected from among guar gum, locust bean gum, karaya gum and gum arbic and pectin are added to 100pts.wt. total of 85-30pts.wt. vinyl acetate (co)polymer (A) such as a vinyl acetate homopolymer or vinyl acetate copolymer of a vinyl acetate content >=70wt.% and a component of other components >=30wt.% each of which has a degree of polymerization of 300-9,000 and 15-70pts.wt. at least one softener (B) selected from among a di(2C or lower alkyl)phthalate, a tri(2C or higher alkyl) citrate and glycerol triacetate, and the obtained mixture is kneaded with a kneader mixer or the like under heating to obtain the title composition composed of component C dispersed in a phase comprising components A and B.
The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as clinically needed. If the volume of the infusion is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death. [ see Dosage and Administration (2)] 

As Acetylcysteine Injection is hyperosmolar (2600 mOsmol/L), caution is advised when the diluent volume is decreased as the hyperosmolarity of the solution is increased. See Table 4 below for examples. 

Single dose vial, preservative-free, discard unused portion. If vial was previously opened, do not use for intravenous administration.

Stability studies indicate that the diluted solution is stable for 24 hours at controlled room temperature.

Note: The color of Acetylcysteine Injection may turn from essentially colorless to a slight pink or purple once the stopper is punctured. The color change does not affect the quality of the product.
FIELD: pharmacy. SUBSTANCE: invention relates to pharmaceutical composition as colloidal nanocapsule suspension containing the oily phase formed by oil that has in solution a surface-active substance and nanocapsules in suspension (diameter is below 500 nM) and involving an aqueous phase formed by solution or suspension of therapeutically active substance, surface-active substance and ethanol in the known cases and the method of making the composition to be proposed. Walls of the above indicated nanocapsules are formed by poly-(2-alkylcyanoacrylate) being alkyl radical of that has from 1 to 6 carbon atoms. Invention provides to obtain microcapsules of decreased size (below 1 mcm) showing the therapeutical activity of substance to be proposed. EFFECT: simplified technology, improved method of capsule making. 17 cl, 2 tbl, 17 ex
Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
The invention relates to a heart disease computer-aided classification method based on statistical manifold curvature, belonging to the field of signal processing technology and computer-aided diagnosis. The method utilizes delay embedding and k-nearest neighbor to convert a one-dimensional electrocardiogram time sequence signal into a point cloud on a positive definite matrix manifold. The method is provided for researching the local structural difference of point cloud distribution by calculating the number curvature of each point and extracting the geometric feature of curvature dispersion, thereby realizing the classification of the original electrocardiogram. The method has high classification accuracy and strong robustness, reduces information loss, avoids the defects of poor interpretability and the like, and fully ensures the application effect. The method can accurately classify a large number of electrocardiograms, greatly reduces the calculated amount and ensures high efficiency. The method does not depend on the selection of parameters and has obvious advantages. The method can be applied to the field of electrocardiosignal classification, and also has wide application prospect in the fields of biomedical research, signal processing and the like.
The invention discloses a traditional Chinese medicinal composition for treating toothache. The traditional Chinese medicinal composition is prepared from the following raw materials in parts by weight: 1-3 parts of all-grass of dandelion, and 58-65 parts of white spirit. The all-grass of dandelion is soaked in the white spirit, wherein the soaking time is shorter than 1d. The all-grass of dandelion and the 53-degree white spirit are adopted as the raw materials. A use method of the traditional Chinese medicinal composition for treating toothache comprises the following step: rinsing the mouth by using the soaked white spirit, 3-5 times a day, and 5-10 ml each time. The traditional Chinese medicinal composition is simple in formula and rapid in taking effect, the operation is easy, the pain can be stopped after rinsing, and the toothache can be radically treated after a few days.
The invention discloses a traditional Chinese medicine for treating neurodermatitis. The traditional Chinese medicine for treating neurodermatitis comprises: by weight, 30 to 40 parts of Chinese angelica, 30 to 50 parts of divaricate saposhnikovia root, 20 to 30 parts of fineleaf schizonepeta herb, 30 to 40 parts of rehmannia root, 30 to 40 parts of radix sophorae flavescentis, 15 to 25 parts of periostracum cicadae, 20 to 30 parts of rhizoma atractylodis, 20 to 30 parts of rhizoma anemarrhenae, 20 to 30 parts of millettia speciosa root, 20 to 30 parts of cortex phellodendri, 20 to 30 parts of caulis lonicerae, 20 to 30 parts of broom cypress fruit, 30 to 40 parts of gypsum, 20 to 30 parts of leapedeza bicolor. turcz. and 30 to 40 parts of talcum, wherein Chinese angelica is utilized as a monarch drug; divaricate saposhnikovia root and fineleaf schizonepeta herb are utilized as minister drugs; rehmannia root, radix sophorae flavescentis, periostracum cicadae and rhizoma atractylodis are utilized as assistant drugs; and rhizoma anemarrhenae, millettia speciosa root, cortex phellodendri, gypsum, caulis lonicerae, broom cypress fruit, leapedeza bicolor. turcz. and talcum are utilized as guide drugs. The traditional Chinese medicine for treating neurodermatitis has the advantages of convenience of preparation and use, safety, no side effect and low treatment cost. Therefore, the traditional Chinese medicine for treating neurodermatitis is an ideal drug for treating neurodermatitis.
To combat peripheral anticholinergic effects, a quaternary ammonium anticholinesterase such as neostigmine methylsulfate (which does not cross the blood-brain barrier) may be given intravenously in increments of 0.25 mg in adults. This dosage may be repeated every five to ten minutes until anticholinergic overactivity is reversed or up to a maximum of 2.5 mg. Proportionately smaller doses should be used in pediatric patients. Indication for repetitive doses of neostigmine should be based on close monitoring of the decrease in heart rate and the return of bowel sounds. 

If CNS symptoms (e.g., excitement, restlessness, convulsions, psychotic behavior) occur, physostigmine (which does cross the blood–brain barrier) may be used. Physostigmine 0.5 to 2 mg should be slowly administered intravenously and repeated as necessary up to a total of 5 mg in adults. Proportionately smaller doses should be used in pediatric patients. 

To combat hypotension, administer IV fluids and/or pressor agents along with supportive care.   


Fever should be treated symptomatically. 

Following overdosage, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis. In the event of a curare-like effect on respiratory muscles, artificial respiration should be instituted and maintained until effective respiratory action returns.
Acute kidney injury (AKI) occurs in 30-50% of hospitalized patients admitted to the intensive care unit (ICU). Dialysis - also known as renal replacement therapy (RRT) - is the only FDA approved treatment for AKI and continuous RRT (CRRT) is generally the preferred method of RRT in the ICU. The in-hospital mortality of patients with AKI requiring dialysis in the ICU is over 50% which is much greater than other serious illnesses.Unfortunately, the quality of care delivered to patients with AKI receiving CRRT is poor due to practice variability and lack of quality indicators to assess CRRT performance. Since one of the fundamental purposes of CRRT is to remove the build-up of metabolites that accumulate during AKI, accurate methods to assess solute clearance would be especially valuable. Indeed, development of methods to assess solute clearance during CRRT has been identified as a research priority. Although changes in plasma creatinine has been suggested as a potential quality indicator of solute removal during CRRT, no study has assessed how reductions of plasma creatinine over time compare to the reductions of other plasma metabolites. Thus, the duration of CRRT necessary to achieve adequate solute removal is unknown - in fact, there is not yet even an agreed-upon working definition of what adequate solute removal during CRRT should be. The investigators propose to conduct a prospective, single center study of 112 CRRT patients to determine the effect of CRRT duration on solute removal in order to identify the time at which solute removal has reached steady state. To assess solute removal, 102 metabolites will be determined in the plasma and effluent via untargeted ultra high pressure liquid chromatography coupled to mass spectrometry (UHPLC-MS). Metabolites will be assessed on plasma collected immediately prior to CRRT initiation, and on plasma and effluent collected on days 1, 2, and 3 post-CRRT initiation. Steady state is defined as the time point at which a plasma metabolite is not significantly reduced during CRRT - as assessed over a 24 hour time period. Based on preliminary data, the investigators hypothesize that \>90% of metabolites will reach steady state by day 2 of CRRT, and that \>95% of metabolites will reach steady state by day 3 of CRRT.